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Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of the 
pandemic coronavirus disease 2019 (COVID-19) that exhibits an overwhelming contagious  
capacity  over other Human Coronaviruses (HCoVs). This structural snapshot describes the 
structural bases underlying the pandemic capacity of SARS-CoV-2 and explains its fast motion 
over respiratory epithelia that allow its rapid cellular entry. Based on notable viral spike (S) 
protein features, we propose that the flat sialic acid-binding domain at the N-terminal domain 
(NTD) of the S1 subunit leads to more effective first contact and interaction with the sialic acid 
layer over the epithelium and this, in turn, allows faster viral "surfing" of the epithelium and 
receptor scanning by SARS-CoV-2. Angiotensin-converting enzyme 2 (ACE-2) protein on the 
epithelial surface is the primary entry receptor for SARS-CoV-2, and protein-protein interaction 
assays demonstrate high-affinity binding of the S protein to ACE-2.  To date, no high-frequency 
mutations were detected at the C-terminal domain (CTD) of the S1 subunit in the S protein, 
where the receptor-binding domain (RBD) is located. Tight binding to ACE-2 by a conserved 
viral RBD suggests the ACE2-RBD interaction is likely optimal. Moreover, the viral S subunit 
contains a cleavage site for furin and other proteases, which accelerates cell entry by SARS-CoV-









This article is protected by copyright. All rights reserved
SARS-CoV-2 relative to other HCoVs, and also discusses emerging hypotheses that are likely to 
contribute to the development of antiviral strategies to combat the pandemic capacity of SARS-
CoV-2.
Introduction
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of the 
current pandemic coronavirus disease 2019 (COVID-19). SARS-CoV-2 has a contagious 
capacity greater than any other previous Human Coronaviruses (HCoV). It is the first pandemic-
causing HCoV with unique S protein features and host tropism patterns [1].  However, specific 
questions about why and how this CoV could cause a pandemic, unlike the six previous HCoVs 
[1, 2]. 
We propose here a pandemic capacity model based on the unique structural features of 
the SARS-CoV-2 virion, which is a spherical single-stranded RNA (ssRNA) virus of positive 
polarity with average diameters of 65 (short), 86 (medium), and 97 (long axis) nm [3]. Its 
envelope structure contains an average 26 spike (S) protein trimers protruding from the envelope 
surface with an average distance of 15 nm to each other [3]. The approximately 10 nm-long 
trimeric S protein contains 1273 amino acids and consists of S1 and S2 subunits [3, 4]. The S1 
subunit can be further divided into the N-terminal domain (NTD) and the C-terminal domain 
(CTD) [4].   According to the model presented herein, the highly contagious nature of SARS-
CoV-2 can be explained based on the structural features of the S protein described below. As a 
starting point, the reader is referred to Figure 1, a summary of the structural features of SARS-
CoV-2 S protein that are unique to this virus, as compared to the six previous HCoVs that did not 
reach pandemic potential. Briefly, these include a) the high binding affinity of the receptor-
binding domain (RBD) to angiotensin converting enzyme-2 (ACE-2); b) the flat and non-sunken 
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furin proteases. Each of these is detailed more in the discussions to follow.
1.SStructural Features of SARS-CoV-2 Unique Among the HCoVs
1.1. Tight binding to entry receptor ACE2 
After exploring the cell surface, SARS-CoV-2 preferentially binds to the entry receptor 
ACE2, utilizing the critical S protein S1 subdomain residues K417, G446, Y449 L455 F486 
N487 Y489 Q493 Q498 T500 N501 G502 and Y505 (Figures 2b, 3 and 4) [5]. In addition, both 
structural models and mass spectroscopic analysis suggested that the N-glycans at residues N165 
and N234 promote a configuration change of the S protein from the "down" state to the receptor-
accessible "up" state [4, 6]. The SARS-CoV-2's S protein has a tighter binding affinity for ACE2 
compared to the genetically closest BatCoV RaTG13 and SARS-CoV [7, 8]. The tight binding is 
also evident from the mutational analysis of more than 100,000 sequences of SARS-CoV-2, 
which did not demonstrate any high-frequency mutation on the RBD of the S protein 
(bigd.big.ac.cn/ncov/). The S protein of other CoVs has high-frequency hot spots for amino acid 
replacements that are referred to as positive selection sites subject to changes during host tropism, 
resistance to antibodies, or immune evasion [9]. Interestingly, in clinical isolates of SARS-CoV-2, 
the only reported S protein mutation was the D614G mutation, which increased host cell entry 
via ACE2 and Transmembrane Protease Serine 2 (TMPRSS2), but decreased susceptibility to 
antisera neutralization [10].  
In contrast, within SARS-CoV-2 isolates, the S protein's NTD and RBD genomic 
compositions are continuous, which means that these regions of the S protein are not subject to 
any high-frequency mutations. Therefore, a significant part of the viral population has the same 
amino acid composition of the RBD as the first Wuhan isolate, despite millions of infections. This 
is likely due to the preservation of an optimal ACE2 receptor-RBD binding interaction and is 
postulated to be the reason for low-frequency mutations in this region of the S protein [1].
1.2. Flat sialic acid-binding domain of SARS-CoV-2
Sialic acids are the common name of a group of acidic sugars, usually located at the end 
of epithelial glycoconjugates and carbohydrate chains [11]. A plethora of viruses use sialic acid 
as part of their infection cycle [12]. Typically, the S protein NTD of HCoVs mediates weak and 
reversible interactions via low-affinity hydrogen bonds with the surface glycans such as sialic 
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binding site is masked under the S protein surface or even sacrificed to evade host cell immunity 
[12]. In SARS-CoV, S Protein NTD has amino acid substitutions, compared to its putative parent 
virus Bat CoV, which has no known sialic acid binding activity [14]. In contrast, the SARS-CoV-
2 NTD has a structural ribbon formation similar to that of human galectins (galactose-binding 
lectins), which are sugar-binding proteins [12]. 
Therefore, the flat surface of the 290 amino acid residue-long NTD of SARS-CoV-2 S 
protein may enhance or promotes the prefusion state of S protein sialic acid-binding capacity, and 
thereby promotes faster viral surfing compare to other HCoVs (see Figure 2 to 4) [15, 16].  
Indeed, Fantini et al. proposed that SARS-CoV-2 is binding not only to the free state siliac acid 
reisdues over the epithelium, but it also interacts with sialoproteins, glycoproteins, and 
gangliosides that contain sialic acid domains covered predominantly with Neu5Ac [16]. 
Additionally, the dual and even triple binding of SARS-CoV-2 to ACE-2 receptor with 
gangliosides present over lipid rafts, which might form a trimolecular complex with the ACE-2 
receptor for more effective entry [16]. 
The S protein NTD of SARS-CoV-2 is localized at residues 14–305 in the S protein, and 
the most critical residues for sialic acid-binding were projected as D111, S112, K113, Q134, 
F135, C136, N137, F140, G142, E156, F157, R158, Y160, S161, and S162 (see Figure 2a) [16]. 
It was further noted that  SARS-CoV-2 S protein variants Q134, F135 and N137, also named as 
“QFN triad residues” bind to the sialic acid domain of gangliosides [17]. Additionally, SARS-
CoV-2 S protein NTD has been suggested to have another sugar receptor-interacting motif G72, 
T73, N74, G75, T76, K77, and R78 is present in other viruses (Figure 2a) [18]. In addition, 
SARS-CoV-2 NTD residues E154, F157, and Y160 have similarity to the bovine coronavirus 
(BCoV) S protein NTD sugar-binding site, which interacts explicitly with sialic acid derivate 
Neu5,9Ac2 (Figure 2a) [18]. The flat surface of the sialic acid-binding domain is likely a critical 
pandemic potential factor that accelerates the initial interaction and viral surfing motion of 
SARS-CoV-2 over the epithelial surface and promotes more effective interaction with proteins 
having sialic acid domains such as gangliosides. Since the S protein sways over the virion 
membrane with a major tilt angle of 40 degrees, it is believed that the initial interaction point of 
the S protein with the epithelium is the NTD [3]. Table 1 summarizes the active S protein 
residues involved.
1.3. Cleavage by proteases
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by proteases that act on its S1/S2 domains, leading to the separation of S1 and S2 domains and 
formation of screw-like S2 fusion conformations composed of a spiral of trimeric protomers (see 
Figure 4) [19].  SARS-CoV-2 has a 4 amino acid long insert (PRRA) on its S1/S1 site that 
enables furin protease cleavage over the residues P681 to S686 (Figure 2c) [20]. The action of 
TMPRSS2, the primary serine protease in many epithelial cells, enhances the cell fusion and 
entry capacity of SARS-CoV-2 compared to the closest genetically related bat virus, RaTG13, 
which lacks a furin cleavage sequence in its S protein [1, 20]. 
             It has been suggested that the leading proline (P) residue of the SARS-CoV-2 S1/S2 
domain improves the protease active site accessibility and thereby promotes cleavage, not only 
by furin but by other proteases [21]. These authors also showed that the SARS-CoV-2 S protein 
could be cleaved by other proteases that cannot cleave the SARS-CoV S proteins [21]. In 
addition to furin proteases, SARS-CoV-2 can be cleaved by TMPRSS2, serine endoprotease 
proprotein convertase 1 (PC1), trypsin, matriptase (trypsin-like integral-membrane serine 
peptidase), cysteine proteases cathepsin B, and cathepsin L [21]. SARS-CoV-2 S protein's 
capacity to be cleaved by a wider variety of proteases compared to SARS-CoV is a key factor in 
its host cell entry through the ACE-2 pathway and is likely an essential factor in its pandemic 
capacity (Figures 3, 4 and Table 1).
2. Emerging Hypotheses on the Structural Basis of SARS-CoV-2 Pandemic Capacity
2.1. Binding to heparan sulfate proteoglycans
In addition to sialic acids, the epithelial surface contains negatively charged linear 
polysaccharide heparan sulfate proteoglycans (HSPGs) used by viruses for cell surface attachment 
[22]. Both the prefusion and ACE2-bound states of SARS-CoV-2 were suggested to be interacting 
with HSPG for cell surface attachment and cellular entry. Clausen et al. reported the HSPGs as a 
co-factor for SARS-CoV-2 S protein binding to the ACE2 entry receptor.  It was proposed that 
positively charged amino acid residues on S protein RBD, close to the ACE2-binding site, are 
potential heparin-binding sites [22]. Software predictions based on heparin-protein contacts and 
energy contributions implicated the positively charged residues on S protein of R346, R355, K444, 
R466, and R509. Other residues contributing to heparin-binding include F347, S349, N354, G447, 
Y449, and Y451 (Figure 2b). Therefore, HSPGs increase the system proton load and trigger the S 
protein transition from the "closed" inactive RBD conformation to the "open" state that facilitates 
ACE2-binding [22, 23]. Indeed, preparations of heparin, unfractionated heparin, non-anticoagulant 
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SARS-CoV-2 infection in vitro. These results underscore the vital role of HSPGs for COVID-19 
disease progression [22]. The same authors also noted that the S protein RBD of SARS-CoV does 
not have an electropositive surface like that observed in SARS-CoV-2. 
However, another molecular interaction model was predicted for SARS-CoV-2 and the 
oversulfated polysaccharides termed glycosaminoglycans (GAGs,) with such GAG-binding being 
promoted by the presence of the GAG-binding-like motifs [23].  Kim et al, predicted sites of 
SARS-CoV-2 S protein that can be involved in HSPG binding. The first location overlaps with 
that predicted by Clausen et al. on the residues Y453, R454, L455, F456, R457, K458, and S459 
(see Figure 2b), when the S protein is in the "up", open or receptor-accessible conformation [23]. 
However, Kim et al. also proposed an additional function of the furin binding insert RRAR 
forming an XBBXBX (PRRARS) GAG-binding motif on the S1/S2 domain on S protein. This 
motif includes the residues P681, R682, R683, A684, R685, and S686 (Figure 2b) [23]. The 
insert P681 to A684 is a polybasic site that provides a structural interaction region on S protein to 
negatively charged HSPGs and possibly to the sialic acids. These polybasic sites on the SARS-
CoV-2 S protein are, in a sense, analogous to the phosphorylation sites of proteins being 
activated with ATP. 
This constitutes another unique functionality of the SARS-CoV-2 subgenus, in addition to 
its furin mentioned above protease interaction capacity. Some of the GAG-binding proteins 
contain specific amino acid sequences' XBBXBX,' and 'XBBBXXBX', also known as Cardin-
Weintraub motifs correspond to the furin cleavage motif BBXBB of SARS-CoV-2 and is not 
present in SARS-CoV or MERS-CoV [23]. Besides, the third HSPG-binding site was predicted 
on the S protein S2 domain, immediately before the fusion peptide residues S810, K811, P812, 
S813, K814, R815, and S816 on the S2 proteolytic cleavage site that is functional in cell entry 
(see Figure 2c) [23]. When combined with the model of Clausen et al., HSPGs might also 
increase the negative charge of the GAG-binding domain of the S2 and promote cell entry [22, 
23]. The SARS-CoV-2 S protein has two different perfusion states; one is the receptor-accessible 
"up" configuration, and the other is the receptor-inaccessible "down" configuration state [19]. It 
is speculated that a SARS-CoV-2 virion with structurally available surface areas and polybasic 
domains could use negatively charged sialic acid and heparan sulfate molecules with free 
electrons to transition into the receptor-accessible "up" state more effectively, and this might be 
another factor underlying its pandemic capacity (Figures 2 to 4).
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Another functionality of the S1/S2 insert unique to the SARS-CoV-2 S protein is forming 
a C-terminal end (residues 676-TQTNSPRRAR-685) RXXROH motif downstream of the furin 
cleavage. This motif was shown to be the binding site for neuropilin 1 (NRP1), a "detour" entry 
receptor over olfactory neuronal cells of the nasal epithelium that functions without using ACE2 
[24]. Epstein–Barr virus (EBV) enters nasopharyngeal epithelial cells through NRP1 with 
macropinocytosis and lipid raft-dependent endocytosis; therefore, SARS-CoV-2 might also use 
NRP1 associated with the lipid rafts for its host cell entry [25].
2.3. Viral escape pathway based on C-type lectin receptors
As aforementioned, many viruses have structural features designed to limit their 
interaction with host surface sialic acids to prevent detection by the immune receptors such as C-
type lectin receptors (CLRs), which are specialized on the pathogenic sialic acid interaction [12, 
26]. As viruses are essentially protein/nucleic acid complexes with no active mobility, they 
utilize their hosts' surface components such as sialic acids, protease enzymes, and other proteins 
for entry into their host cells. However, perhaps the most clever and self-serving strategy 
employed by viruses to capitalize on host elements is the use of C-type lectin receptors (CLRs) 
for cell entry [26]. After endocytosis, some viruses intended for viral degradation find a way to 
survive by using immune receptors as a pathway for infection, a process is known as "viral 
escape" [26]. The uniquely flat sialic acid interaction of SARS-CoV-2, which we hypothesize 
allows faster viral surfing, might also provide an unexpected advantage to the virus through the 
CLRs promoting a higher rate of not only cell entry, but also viral escape. 
Watanabe et al. proposed that the relatively fewer N-linked glycosylation sites of the S 
protein of SARS-CoV-2, compared to HIV-1 Env and Lassa virus (LASV) S proteins, could be 
associated with higher viral detection by CLRs and might explain the lower fatality of SARS-
CoV-2 relative to those viruses [6]. SARS-CoV-2 was found to interact with CLRs, Cluster of 
Differentiation 209 (CD209L) /liver/lymph node-specific ICAM-3 grabbing non-integrin (L-
SIGN),  and CD209 /dendritic cell-specific ICAM-3-grabbing nonintegrin (DSIGN) as "detour" 
entry receptors, all acting through the S protein RBD [27]. Similar interactions were detected in 
SARS-CoV bound to the DC-SIGN receptors over the S protein residues 363 to 368, N-linked 
glycosylation sites N330 and N357, and residues 435 to 439 [28]. Amraie et al. did not 
investigate the putative DSIGN interacting residues; however, based on the ClustalW alignment, 
it suggested that the SARS-CoV residues 363 to 368 (TFKCYG) are identical to SARS-CoV-2 
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N344 of SARS-CoV-2, N357 of SARS-CoV is identical to N371 of SARS-CoV-2, and the 
SARS-CoV residues on 435 to 439 NYNY are identical to SARS-CoV-2 residues on 448 to 451. 
These similarities suggest that the conserved interacting residues with D-SIGN CLRs act within 
the Sarbecoronavirus subgenus (Figure 2b). 
Strikingly, S protein glycosylation at the residues N227 and N699 (residues N234 and 
N707 in SARS-CoV-2) increased DC/L-SIGN-mediated pseudovirus entry into cultured cells and 
was suggested to have a role in SARS-CoV host tropism from civets to humans [29]. The 
analogous residues of SARS-CoV-2 that are important for increasing the DC/L-SIGN-mediated 
cell entry are all oligomannosylated [6, 27, 28]. This was expected because DC/L-SIGN 
preferentially recognizes oligomannose [29].  Therefore, it seems plausible that the combination 
of effective sialic acid-binding and the CLR-dependent viral entry mechanism of SARS-CoV-2 
may constitute a distinct pathway that does not require ACE-2 receptors or protease cleavage and 
might be an essential factor underlying the pandemic capacity of SARS-CoV-2 (Figure 3). 
Indeed, Fantini et al. proposed the dual binding of the virus to gangliosides and adjacent ACE-2 
[16]; however, D-SIGN CLRs are also found on lipid rafts, and therefore the lipid raft might also 
be an essential contributor to the viral escape entry pathway [ 30]. In light of the finding that type 
II alveolar cells of the lung, respiratory dendritic cells, and associated endothelial cells are rich in 
CLRs, it seems plausible to theorize that CLRs are related to the pandemic capacity of SARS-
CoV-2 [31].
With potential relevance to Central Nervous System pathology in COVID-19, previous 
studies have shown the direct involvement of the mannose receptor, a type of CLRs, in HIV-1 
astrocyte infection, and suggested that the interaction of HIV-1 with this receptor plays an 
important role in the neuropathogenesis of HIV-1 [32]. In another study, it was established that 
the phagocytic pathway dependent on the binding of mannose-rich carbohydrates of gp120 to the 
MR expressed in the microglia leads to the non-replicative entry of HIV-1 [33]. It is currently 
widely known that HIV-1 infection in the brain usually occurs in monocytes/macrophages 
(migrating) and microglia in an MR-mediated manner. In contrast, a less-vigorous infection 
occurs in astrocytes, which are also highly reactive in producing compounds toxic to neurons. It 
is known that HIV-1 does not infect neurons [34, 35].
On the other hand, it cannot be ruled out that during infection of SARS-CoV-2 in the brain, 
the MR may be involved through its expression in microglia and astrocytes. In a hypothetical 
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between SARS-CoV-2 and glial cells through the expression of MR or other pattern recognition 
receptors (PRRs). Numerous reports reinforce brainstem infection as the leading cause of 
respiratory failure in patients affected by Covid-19 [36]. Since CLRs and other PRRs are 
recognized to play a critical role in the innate immune signaling pathways, their involvement in 
COVID-19-related systemic hyper-inflammation could be influencing neurovascular endothelial 
function, breakdown of the Blood-Brain Barrier, and activation of the CNS innate immune 
response. All these mechanisms might contribute to CNS complications associated with SARS-
CoV-2 infection [36]. However, the cellular and molecular components of these disorders still 
need to be clarified.
2.4. Hypothetical lipid raft-dependent endocytosis
 The lipid rafts are sphingolipids and cholesterol rich domains on the fluid mosaic model of the 
plasma membrane [37]. Cellular and/or exogenous proteins uses lipid rafts for mobility over cell 
surface. Lipid rafts are usually associated with singal receptor domains (signalosomes) of the 
plasma membrane [37]. Many viruses use lipid rafts for binding, cell entry, assembly, and exit 
[38], and  SARS-CoV cell entry through the lipid rafts was detected on Vero cells [39]. Lipid raft 
dependent structural model of virus-host interactions has been developed by Fantini et al. for 
human immunodeficiency virus 1 (HIV-1)  on CD4 T cells [37]. In the model, HIV-1 surface 
envelope glycoprotein gp120 complex with CD4 membrane protein interacted with adjacent co-
receptors over the membrane such as chemokine receptors CXCR4 or CCR5 [37]. The dual 
interaction between the HIV-1 gp120 with CD4 and co-receptor first triggers lipid raft mediated 
repulsion over the surface of the T cell and a conformational changes of the HIV-1 thus 
unmasking fusion protein gp41 [37]. Therefore, SARS-CoV-2 may experience similar membrane 
tension with lipid raft mediated repulsion through S protein ACE-2 especially when lipid raft 
contains gangliosides or even other lipid raft localized signal receptors such as CLRs, NRP1, and 
perhaps integrins [16, 17, 37]. Considering the mobile nature of lipid rafts through the mosaic 
membrane, SARS-CoV-2 S protein ganglioside rich lipid rafts over the epithelium surface could 
act as a surf board during the viral surfing [16, 17, 25, 30, 37]. Therefore, it is quite plausible that 
SARS-CoV-2 might use lipid rafts for viral surfing over the epithelium and lipid raft-dependent 
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The model described herein of the pandemic capacity of SARS-CoV-2 is based on the following 
structural features unique to SARS-CoV-2: a) flat sialic acid-binding domain enables faster viral 
surfing over the epithelial surface before receptor interaction; b) tight and almost perfect binding 
to the ACE2 entry receptor; c) the capacity to use furin and other proteases for cell entry. Other 
factors which are likely to contribute to the pandemic capacity of SARS-CoV-2 included d) 
binding to HSPGs through several different sites; e) binding to CLRs for viral escape-based 
"detour" entry without cleavage by protease; f) NRP1-based detour entry without ACE2 
involvement; g) possible lipid raft-dependent endocytosis through gangliosides and CLRs 
(Figures 3-4). SARS-CoV-2 can move rapidly over the cell surface by a significant interaction 
with surface sugars and receptors and may hypothetically be using three or more different 
pathways for cell entry. Therefore, these unique interactions of the SARS-CoV-2 are believed to 
be the critical pandemic capacity factors. On this basis, targets for treatment options may include 
antibodies against S protein NTD to limit sialic acid-binding such as neutralizing antibody (4A8), 
ganglioside binding agents such as hydroxychloroquine, exogenous heparin against HSPGs, 
protease inhibitors, ganglioside mimics such as azithromycin and cholesterol-depleting agents 
targeting lipid rafts such as cyclodextrin [16, 17, 19, 23, 38, 40]. Clearly, more research is needed 
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Function Note Interaction Sesidues on S protein Citations
ACE2 Entry receptor K417, G446, Y449, L455, F486, N487, Y489, 
Q493, Q498, T500, N501, G502 and Y505
[5]
Sialic acid 




D111, S112, K113, Q134, F135, C136, N137, 
F140, G142, E156, F157, R158, Y160, S161 
and S162  
[16]
Sugar binding  Sugar receptor 
interacting motif
G72, T73, N74, G75, T76, K77, and R78 [19]
Sugar 
binding
BcoV sugar binding 
domaing




amino acids motif 
R346, R355, K444, R466, and R509 [22]
HSPGs 
binding 
Supporting residues F347, S349, N354, G447, Y449, and Y451 [22]
HSPGs 
binding 































binding and detour 
entry receptor
Over the receptor binding domain and 
hypothetically binding sites are N344, N371, 







binding and detour 
entry receptor
S1/S2 site, T676, Q677, T678, N679, S680, 





Furin, TMPRSS2,  
trypsin, matriptase 
cathepsin B-L, PC1
P681, R682, R683, A684,R685, S686 and 
V687
[36]










This article is protected by copyright. All rights reserved
Figure Legends 
Figure 1. Summary of the S spike protein structural features unique to SARS-CoV-2 over other 
HCoVs. A: The binding affinity of the spike Receptor Binding Domain (RBD) to its primary 
cellular receptor ACE-2 (angiotensin converting enzyme-2) is more than 10-fold higher than that 
of the SARS-CoV spike RBD. B: The flat, non-sunken sialic acid-binding domain is in conflict 
with that of all other HCoVs, which are sunken in accord with the Canyon Hypothesis. C: The 
S1/S2 domain of SARS-CoV-2 spike protein contains a four amino acid-long insert that 
constitutes a cleavage site for furin proteases, abundant in respiratory epithelia. See text for 
details. The protein model were S protein, down state (PDB ID 6X2C) was modelled with 
ChimeraX [41].
Figure 2. The flat sialic acid binding domain. The epithelium is covered with a sialic acid layer. 
The flat sialic acid-binding domain of SARS-CoV-2 leads to a more effective first contact and 
interaction with the epithelium, which allows faster viral “surfing” of the epithelial surface and 
entry receptor scanning. A: The flat sialic acid, ganglioside and other sugar binding domains 
(white spheres, left panel) are localized on the left side protomer of the S protein (purple oval, 
right panel).  
B: Entry receptor ACE-2 binding domains (red spheres, left panel), C-type lectin receptor (CLR, 
green), HSPG (heparan sulfate proteoglycan) binding domains based on charge interaction (blue) 
and HSPG binding domains based on GAG (glycosaminiglycan)-motif (purple) are localized on 
the top of the peptomer adjacent to the sialic acid binding domain of the S protein (purple oval, 
right panel); 
C: S1/S2 section of the S protein has a unique insert (purple spheres, left panel) that enables it to 
be cleaved by furin and other proteases e.g. TMPRSS2, PC1, trypsin, matriptase, cathepsin B, 
and cathepsin L. This domain is localized over the central section of the S protein (purple oval, 
right panel). Further, another region of the S2 subunit (purple spheres, left panel) has HSPG- 
interaction domains (right side of left panel). In addition, the insert and downstream amino acids 
form a motif capable of binding NRP1 for cellular entry. See text for details. The protein model 
were S protein, down state (PDB ID 6X2C) was modelled with ChimeraX [41].
Figure 3. Cleavage of viral S protein by proteases. After viral surfing over the epithelium sialic 
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acid rich gangliosides was also suggested. Unlike other HCoVs, the SARS-CoV-2 S1/S2 protein 
subdomain contains a four amino acid insert that constitutes an enzymatic cleavage site for furin 
and other proteases, which are abundant on respiratory epithelia. Compared to SARS-CoV, a 
wider variety of proteases (displayed in left side of Figure 3) is capable of cleaving the S1/S2 
subnunit domains of SARS-CoV-2, which is believed to form screw-like S2 fusion 
conformations composed of spiral trimeric protomers (see right side of Figure 4) that facilitate 
host cell entry by SARS-CoV-2. See text for details. The protein models were S protein, S 
protein-ACE2 complex (PDB ID 7A98), S protein S1 subunit with ACE2 (PDB ID 7A92), S2 
subunit postfusion state (PDB ID 6M3W), furin (PDB ID 5JXG), trypsin (PDB ID 3MI4), 
matriptase (PDB ID 4R0I), cysteine proteases cathepsin B (PDB ID 3MOR), and cathepsin L 
(PDB ID 3OF9). The models of TMPRSS2 (UniProtKB – O15393), PC1 (GenBank 
NP_000430.3), were constructed using Swiss-model (https://swissmodel.expasy.org/). The 
structures were modelled with ChimeraX and visualized over Microsoft Paint 3D [41].
Figure 4. Hypothetical roles for heparan sulfate proteoglycans (HSPGs), gangliosides, C-type 
lectin receptors (CLRs), NRP1 and lipid rafts in viral spike protein-epithelial cell interactions. In 
a proposed cell entry mechanism based on CLRs, the S protein moves over epithelium with its 
flat sialic acid binding domain (at left of Figure 4), interacting with free state sialic acids, 
gangliosides and various motifs on HSPGs, primarily though relatively weak interactions such as 
hydrogen bonding. CLRs localized either over the plasma membrane or over lipid rafts (at center 
of Figure 4) interact with the S protein and may bypass ACE-2 and promote virion entry into the 
cell. Some viruses are known to use CLRs for cell entry to avoid degradation by phagocytes, a 
process sometimes referred to as the “viral escape” mechanism. Lipid rafts are known to contain 
many of these components, and thus may also be involved in viral entry. After protease action on 
the S2 subunit, NRP1 localized either over the plasma membrane or over lipid rafts (at right of 
Figure 4) may interact with the S protein and help bypass ACE-2 to promote virion entry into the 
cell. See text for details.
The protein models were S protein, down state (PDB ID 6X2C), S protein S1 subunit (PDB ID 
7CHF), S2 subunit postfusion state (PDB ID 6M3W), CLRs (PDB IDs 1XAR with 3JQH), furin 
(PDB ID 5JXG),  Neuropilin-1 (PBB ID 2QQM), were modelled with ChimeraX and visulaized 
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Table 1. Summary of the interactive residues of the SARS-CoV-2 Spike protein  
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